CHINA FOCUS @JPM WEEK

CHINA FOCUS @ JPMORGAN WEEK

JAN 6, 2019

SAN FRANCISCO
CA

CHINA FOCUS

JW MARRIOTT SAN FRANCISCO UNION SQUARE

515 MASON ST, SAN FRANCISCO, CA 94102

CSPC 石药集团 | McDermott Will & Emery : GOLD SPONSOR

华森制药 : SILVER SPONSOR

GUIDE MAP

CHINA FOCUS



QUICK GUIDE

Track 1	Metropolitan Ballroom B/C	8AM-5PM	Plenary Session
Track 2	Salon I	8AM-5PM	Private Pitch Session
Track 3	Pre-Function	8AM-5PM	Exhibition and Partnering (Booth 1-15)
		12PM-1PM	Lunch Buffet
		5PM-6PM	Reception
Track 4	Metropolitan Ballroom A	8AM-5PM	Partnering (Table 16-30)

- Track 1: Plenary Session
- Track 2: Private Pitch Session
- Track 3: Exhibition and Partnering Area (Booth 1-15)
- Track 4: Partnering Area (Table 16-30)



Registration and Information Desk

Exhibitor List

① Brochure/Flyer Display
② Process Record Slide
④ Madison Vaccines Incorporated (MVI) Brochure/Flyer Display
⑥ Elasmogen Ltd
⑦ MGI
⑧ Histogen
⑨ Pharscin Pharma
⑪ Atom Bioscience
⑫ Viriom
⑭ GLAdiator Biosciences
⑮ ThermaGenix

Dear friends,

On behalf of the MyBioGate team, I would like to welcome you to China Focus Forum, a platform to exchange ideas and foster collaborations across the pacific.

China has seen vigorous growths in its drug and medical devices industry in recent years, however, there is still a long way to go. To intensify the structural reform occurring in the drugs and medical devices industry, promote technological innovation, augment the industry' s competitiveness and meet the clinical needs of the general public, China has adopted far-reaching reforms in the evaluation and approval system as well as funding mechanisms.

In 2017, China joined the ICH as a full regulatory member in an effort to actively promote the timely entry of international drugs into the Chinese market, and to support the innovation and competitiveness of its domestic pharmaceutical industry. In 2018, Hong Kong cleared way for pre-revenue biotech IPOs, 4 companies already listed on HKEX by Dec, 2018. Meanwhile, NMPA (Formally CFDA) continued its initiative of drug evaluation and approval systems, including optimizing clinical trial management, accelerating the evaluation and approval for marketing authorizations, and conducting new generic consistency evaluation (GCE).

Propelled by recent changes in regulatory and funding environments, bringing new therapeutics and technologies to the China market becomes an appealing strategy for all kinds of investors. However, the variations in the geopolitical environment brings challenges to the cross-border collaborations. The Committee on Foreign Investment in the United States (or known as CFIUS) brings additional uncertainties and expenses for both sides to conduct cross-border investments. It becomes critical to understanding the implication and gain knowledge of solutions if you need to consider foreign sources of funding or get access to assets from U.S.

That is why we organized this CHINA FOCUS Forum. It is because both China and the western community have the need for a focused discussion on cross-border collaboration; it is because we need to work together for solutions; it is because you want to be a deal maker.

As a professional service entity, MyBioGate has a mission to bridge China and overseas healthcare innovations. MyBioGate not only supports pharmaceuticals and investors with their oversea strategies, circulates insights about healthcare breakthroughs and publishes industry research reports; but also organizes forums and other partnering events to bring together healthcare executives across the pacific for real business conversations. Our goal is to foster healthcare innovations that could benefit the world through alliances between the east and the west.

Finally, I would like to thank everyone who makes it here. You contribute to this event make it a meaningful platform for every participant. If there is anything our team can do to be of assistance, don' t hesitate to ask.

This is the second China Focus Forum we organized since the first event in Boston last Sept. We' ve lined up 5 events in 2019 in both U.S. and Europe. I look forward to seeing you again in Vienna, Philadelphia, Boston, and Hamburg in our future events.

Thank you!

Sincerely,

Shautong Song, Ph.D.
Managing Director
MyBioGate, Inc.

EVENT CONTENT

CHINA FOCUS

CONTENT

TIME	TOPIC	SPEAKER
7 :00-8:00	Check-in	
8:00-8:20	Opening Remarks	Shautong Song, Managing Director, MyBioGate
8:20-9:00	Keynote: China' s Role in Global Life Science & Healthcare	Katherine Andersen, Head of Healthcare Corporate Finance and East/Central Life Science, Silicon Valley Bank
09:00-09:45	Panel 1: Money from the East: Opportunities and Challenges in Cross-border Collaboration	Kim Nearing, Managing Director, Cedrus Group (Moderator) Adam Zhao, Partner, Anlong Medical Fund Irene Hong, Founding Partner, CEC Capital Group James Huang, Managing Partner, KPCB China Geffrey Gao, Executive VP/Deputy GM, Head of Strategy, BD, Investment and M&A Company, Harbin Pharmaceutical Group
9:45-11:05	Emerging Company Pitch	
11:05-11:15	Break	
11:15-12:00	Panel 2: Partnering Opportunities with Chinese Pharma Companies	Bob Ai, Senior Vice President, Solebury Trout (Moderator) Qingxi (Charles) Wang, President, International Division, CSPC Pharmaceutical Group Ltd Anjiang Liu, Senior Advisor, Fosun Pharma Dang Qun, Global BD Head, Qilu Pharma Weigang Wang, Senior Director, Global Pharma Business Development & Licensing, Chia Tai Tianqing Pharmaceutical
12:00-13:30	Lunch Break	
12:50-13:10	Lunch Talk: Navigating Beyond Borders: Key Strategic Considerations for China BioPharma in a Global Market	James Lee, Associate Principal, Oncology Lead, Cello Health BioConsulting
13:30-14:15	Panel 3: Selling to the West: Fund raising, Out-licensing and IPO Opportunities for China' s Biotech Innovations	Dennis Purcell, Founder and Senior Advisor, Aisling Capital (Moderator) Yuanhua Ding, Head of External R&D, Pfizer Aaron Chen, Senior Director, Global Business Development & Licensing, Oncology, Bayer Pharmaceuticals Linus Lin, Vice President, China Research; Head of Lilly China Innovation and Partnerships (LCIP), Eli Lilly and Company Scott Liu, CEO, Henlius Simon Xu, CFO 3D Medicines Inc.
14:15-16:05	Emerging Company Pitch	
16:05-16:15	Break	
16:15-17:00	Panel 4: Current Healthcare Venture Capital Trends & Opportunities	Daniel Chai, Managing Partner, Turret Capital Management (Moderator) Nissim Darvish, Senior Managing Director, OrbiMed Advisors Cynthia Cai, Senior Advisor, Northern Light Venture Capital Linda Ji, Partner, McDermott Will & Emery LLP
17:00-18:00	Reception	

SPEAKER
CHINA FOCUS

KEYNOTE

Chinas Role in Global Life Science & Healthcare

Katherine Andersen

Head of Healthcare Corporate Finance and East/Central Life Science, Silicon Valley Bank

Katherine sits on the Board of Directors for SVB's China JV. Prior to SVB, Katherine was a Senior Vice President for Wells Fargo Bank leading the Life Sciences business development and relationship management efforts for the New England region. Before that, she was a Director at Wells Fargo Capital Finance focused on front-end business development and underwriting of structured loans, ultimately totaling over $3.0B in commitments. Prior to Wells, she held various positions across mergers and acquisitions, finance, equity derivatives, audit, and management while at Affiliated Managers Group, Merrill Lynch, GE Corporate Audit Staff and GE Capital.

Katherine has a bachelor' s degree in finance and economics from Virginia Tech. She has also completed Dartmouth' s Tuck Executive Leadership and Strategic Impact Program, Wells Fargo' s Transformational Leadership Program, the Program on Negotiation at Harvard Law School and the GE Capital Financial Management Program.

Away from work, Katherine serves on the Finance Advisory Board for Virginia Tech and the Corporate Council for the American Cancer Society' s Hope Lodge. She also enjoys endurance sports, traveling the world with her family, and baking epic birthday cakes for her three kids.

PANEL - 1

Money from the East: Opportunities and Challenges in Cross-border Collaboration

Kimberly A. Nearing (Moderator)

Managing Director, Head of Life Sciences, Cedrus Group
Regional Leader for BayHelix' s NY/NJ/PA Chapters

Kimberly Nearing has over 20 years of life sciences experience, including in the capacity as a senior operations manager, an investor, an investment banker and a consultant. Currently, as the Managing Director, Head of Life Sciences at the Cedrus Group, a global boutique investment firm headquartered in Hong Kong with offices in Shanghai, and Beijing, Kim is actively engaged in international business and finance activities, particularly in the Greater China and the Gulf Cooperation Council (GCC) regions. She is also the regional leader (NY/NJ/PA) for BayHelix, an invitation-only organization of leaders of Chinese heritage in the global life sciences and healthcare community.

Adam Chunlin Zhao

Partner, Anlong Medical Fund

The founder and managing partner of the ANLONG fund. Dr. Zhao graduated from Biological Science and Technology department at Tsinghua University. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and master' s degree of business administration at University of Chicago in the United States. Dr. Zhao served as medical investment adviser at Office of Technology Transfer at University of Pittsburg and senior manager at Pfizer. After returning to China, he founded Beijing LongMed biological technology

co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, investing in BerryGenomics, Innovent Biologics, ASLETIS, GKHT Medical Technology and so on.

Irene Hong

Senior Director, Global Pharma Business
CEC Capital Group

Ms. Hong is a founding partner for CEC Capital Group, and leads the healthcare industry group. Under her guidance, CEC Capital has emerged as a leader in the healthcare banking sector with the largest specialized team covering pharma/biotech, medtech, services, and digital healthcare. Notable clients include Arrail Dental, Berry Genomics, China Medical Diagnostics Corporation, Righton Bio, Sino-Kor Hospital, and Reach Surgical. CEC Capital also has a strong cross-border practice, having worked in the past with several multinational companies including Zimmer, Charles River, and Teva. With an increasing interest in China outbound investment, CEC Capital has opened an office in the US and Ms. Hong will be leading this cross-border effort.

James Huang

Managing Partner, KPCB China

James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm' s life sciences practice. James has made more than 15 investments in China since 2007. Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

Geffrey Gao

Executive VP/Deputy GM, Head of Strategy, BD, Investment and M&A Company, Harbin pharmaceutical group

Dr. Lei Gao has a unique background with a combination of biomedical research, management consulting, investment banking, financial investment and M&A. Originally trained as a scientist, Lei earned his Ph.D. in Pharmacology at Brown University and received post-doctoral training in Neuroscience at the University of Pennsylvania.

In 2015, Dr. Gao came back to China and joined Tasly Pharma/Tasly Capital as the head of international investment. Over a period of 3 years, he successfully consummated transactions in all major markets including the U.S., China, Europe, Canada, and Australia. In September 2018, Dr. Gao joined Harbin Pharma as an EVP/Deputy GM responsible for strategy, BD, investment and M&A.

PANEL - 2

Partnering Opportunities with
Chinese pharma companies

Bob Ai (Moderator)

Senior Vice President, Solebury Trout

Bob joined the Trout Group in September 2016 and focuses on the Sino-US cross-border banking and strategic consulting service (mainly licensing) and investor

SPEAKER
CHINA FOCUS

relations. Prior to joining Trout, he was managing director, senior biotech analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company. He has also served as Principal in crossover life science privateequity firm Merlin Nexus and senior equity analysts at assets management firms Bennett Lawrence and Merlin Biomed Group.

Anjiang Liu

Senior Adivsor Wanbang Biopharmaceutical, Deputy Genernal Manager, Strategic Product Development Center, Shanghai Fosun Pharmaceutical Development Co., Ltd.

Dr. Liu worked in International Business Division and Wanbang Biopharmaceutical of Shanghai Fosun Pharmaceutical Group in 2009. His achievements including helping the company to raise a $500 million private equity fund from oversea and setting up two JVs with large US and Canadian companies in China, investment in healthcare service company in the US and completed several pharmaceutical business development transactions which could potentially bring to Chinese market total over $1 billion revenue product opportunities in the future.

Qun Dang

Vice President, Global Head of BD and External Innovation, PR&D, Qilu Pharmaceutical

Max received his BS from Jilin University with honors and earned a CGP national scholarship sponsored by the Chinese government; he obtained his Ph.D. in organic chemistry from Purdue University in 1992. In his current role at Qilu, he is responsible for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. Max has extensive experiences in business development globally and more than 20-years of experiences as a manager of drug discovery programs spanning early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; Phase 2b studies).

Weigang Wang

Senior Director, Global Pharma Business Development & Licensing, Chia Tai Tianqing Pharmaceutical

Dr. Weigang Wang has been the Senior Director of Global Pharma Business Development & Licensing at Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and General Manager, Overseas Investment at CP Pharmaceutical Group, Sino Biopharm and Chia Tai Pharmaceutical Investment Co., LTD. since 2016, following 9 years as a scientific team leader at ImClone Systems/Eli Lilly, where he held various leadership positions in spearheading IND enabling R&D activities. Dr. Wang also has over 10 years of academic research experience at Albert Einstein College of Medicine, and Peking Union Medical College, where he published numerous impactful papers in prestigious scientific journals, and is recognized as an expert in cancer signaling, invasion and metastasis, and antibody based therapy.

Weimin Tang

Global Business Head and Business VP, I-Mab Biopharma

Dr. Weimin Tang is currently EVP of I-MAB Biopharma, a clinical stage biotech company focus on Immunology and Oncology. He served as Head of US Business Development/Executive Dir. Jiangsu Hengrui Medicine previously and build Hengrui global business development team and clinical operation in Princeton, NJ. He was trained as cancer biologist with PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management.

LUNCH TALK

Navigating Beyond Borders: Key Strategic Considerations for China BioPharma in a Global Market

James Lee

Associate Principal, Oncology Lead, Cello Health BioConsulting

James has extensive research, commercial, and strategic perspective on the pharmaceutical and biotech industries. He has a strong expertise in oncology, particularly immuno-oncology, where he has led many client engagements ranging from commercial opportunity assessments to portfolio/platform management. He has helped clients navigate many potential BD&L issues, ranging from in- and out-licensing opportunities and evaluating precommercial biotech clinical development paths. Before joining Cello Health BioConsulting, James was an Oncology Personalized Medicine Project Leader and Scientist at Psychogenics, where he was involved in numerous preclinical neuroscience and translational oncology projects.

PANEL 3

Panel 3: Selling to the West: Fundraising, Out-licensing and IPO Opportunities for China' s Biotech Innovations

Dennis Purcell (Moderator)

Founder and Senior Advisor, Aisling Capital

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Yuanhua Ding

Head of External R&D, Pfizer

Dr. Yuan-Hua Ding is an Executive Director and Head of Pfizer External Science & Innovation (ES&I) – Asia/Pacific, Pfizer Worldwide Research & Development (WRD). He is also a member of the ES&I leadership team. In this capacity, he and his team partner with colleagues in ES&I, Pfizer Business Development Group, Pfizer Venture Group and Pfizer Asia Country Offices to evaluate technologies and assets from academic, biotech & pharma laboratories, seek opportunities to incubate early biotech companies, build and manage an external network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks. He liaises with therapeutic area and technology research unit leaderships in accessing the sciences, technologies and products needed to support Pfizer R&D mission. Dr. Ding also manages WRD' s Asia Innovation Fund which enables academic collaborations, biotech alliances and NewCo seeding with Asia partners. Asia/Pacific.

Aaron Chen

Senior Director, Global Business Development & Licensing, Oncology, Bayer Pharmaceuticals

Dr. Aaron Feng Chen is currently Senior Director of Global

SPEAKER
CHINA FOCUS

BD&L at Bayer Pharmaceuticals, accountable for leading business development, licensing and clinical collaboration efforts in Oncology. Dr. Chen has 15+ years of experience in academia, consulting, biotech, and pharmaceutical industries. Dr. Chen has been with Bayer since 2010 with increasing responsibilities in Strategic Planning, Market Access, Marketing, and Business Development. He played a critical role in establishing and executing the Loxo partnership on Vitrakvi® (larotrectinib), the Janssen partnership on Xarelto® (rivaroxaban), and partnership with Merck and Roche on multiple oncology clinical collaborations. Prior to Bayer, Dr. Chen worked at McKinsey & Company as a consultant, assisting large pharma clients with development of R&D, marketing, sales and strategic recommendations. Development. He played a critical role in establishing and executing the Loxo.

Linus S Lin

Vice President, China Research; Head of Lilly China Innovation and Partnerships (LCIP)
Eli Lilly and Company

Dr. Linus S. Lin is currently VP-China Research of Eli Lilly & Co. He leads the newly created Lilly China Innovation and Partnerships, a group that is designed to engage industry and academic collaborators in China to accelerate innovation and catalyze value creation.

Prior to Lilly, Dr. Lin was Vice President of Operations andChemistry and Global Head of Chemistry Technology and Services at WuXi AppTec. He led a business unit of over 1500 scientists, established/maintained business collaborations that included every major pharma company and 100s of biotech/non-profit/academic research institutions, and helped to build the top discovery CRO brand in the industry.

Dr. Lin started his industry career as a medicinal chemist at Merck Research Laboratories, rising to Global Chemistry Operations Lead. He was also a founding member of the External Basic Research unit at Merck, which was tasked to deliver a quarter of the discovery pipeline through external collaborations.

Scott Liu

CEO, Henlius

Dr.Liu has previously served as a VP of R&D of United Biomedical, the fouding director of the Biologics QC department of Bristol-Myers Squibb-Syracuse, and the QAL (QC) director of Amgen-Fremont. Dr. Liu was a key member of the CMC teams for the late-phase development and commercial cGMP manufacturing of Orencia and Vectibix. Because of his outstanding achievement, Dr. Liu has won the Bristol-Myers Squibb Company's Tech Ops President Award.

Liu Scott has 23 years of experience in biopharmaceutical R&D, regulatory affairs and quality operations. At the same time, Dr. Liu assisted the formation of "Quality Alliance of Protein Therapeutics" and helped the CDE of CFDA in the establishment and improvement of the quality standards for protein therapeutics in China. Under his leadership, Henlius has been a leader in antibody drug development in China, completing the IND submissions of 8 product candidates with 13 indications.

Simon Xu

CFO, 3D Medicines Inc.

Simon has 13 years work experience in Life Science research, and investment management in hedge fund/private equity/fund of funds, focusing on the US and Greater China healthcare markets; He was the Former Executive Director of China Minsheng Investment Group, invested and managed a global healthcare portfolio of over 250 million USD and sat on boards of directors of several portfolio companies; Simon was the Former Senior Analyst of Lighthorse Aseet Management (HK), the Winner of HFM Asia Hedge Fund Performance Awards 2015; He was the Former Founding Member of BioTechnique, a cytotoxic fill-finish CMO in the US, acquired by LSNE.

PANEL - 4

Current Healthcare Venture Capital Trends & Opportunities

Daniel Chai (Moderator)

Managing Partner, Turret Capital Management

Dr. Chai has close to 20 years of both private and public investment experience in the global healthcare sector. He founded Turret Capital Management in 2016 and previously served as Portfolio Manager at several leading investment firms including Citadel Investment Group, UBS, and Neuberger Berman. Dr. Chai is an investor and co-founder of Serenikey Therapeutics Inc., a private biotechnology company focused on the treatment of neurological diseases. He was an investor and board member of Nexgen Spine Inc., a private medical devices company focused on the treatment of spinal related disorders, which was acquired by K2M Group Holdings (KTWO).

Nissim Darvish

Senior Managing Director, OrbiMed Advisors

Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, andsubsequently conducted his postdoctoral research at the N.I.H. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.

Cynthia Cai

Senior Advisor, Northern Light Venture Capital

Dr. Cai is a senior advisor for Northern Light Venture Capital, a leading venture capital firm for Healthcare, TMT, and Advanced Technologies. She is focused on early-stage investments in the US healthcare segment. Dr. Cai had over 20 years of experience in leadership positions with one of the world' s most respected biotech companies. As senior director of marketing in the Mass Spec. Division for Agilent Technologies, she was responsible for global thought leader collaboration and solution development for its billion-dollar MS business. Before that, as business development manager and product marketing manager, Dr. Cai was involved in multiple acquisitions and divestitures and led a $500+ million-dollar flagship product development and its global commercialization.

Linda Ji

Partner, McDermott Will & Emery LLP

Linda Ji has extensive experience representing domestic and international clients in connection with a wide range of corporate and commercial transactions, with a specialty focus on cross-border deals between China and the United States. Linda has represented multiple Chinese and US companies in a variety of transactions in the US, including corporate structuring, new company formation, equity investments, venture capital financing, debt financings, mergers and acquisitions, IPOs and post-IPO compliance, joint ventures, technology licensing, strategic collaborations, as well as corporate governance, equity compensation and equity incentive plan, and other operational matters. Linda counsels China-based clients in connection with transactions involving US national security analysis and filings with the Committee on Foreign Investment in the United States (CFIUS).

PRESENTING COMPANIES

9:45-9:55	TARGOVAX
9:55-10:05	ETHERNA IMMUNOTHERAPIES NV
10:05-10:15	ASTROCYTE PHARMACEUTICALS, INC.
10:15-10:25	MADISON VACCINES INCORPORATED (MVI)
10:25-10:35	HPBIO INC
10:35-10:45	ELASMOGEN LTD
10:45-10:55	ALPS GLOBAL HOLDING BERHAD
10:55-11:05	HEXAELL BIOTECH

PRENSENTING COMPANIES

14:15-14:25	MGI/BGI
14:25-14:35	HISTOGEN
14:35-14:45	PROMIS NEUROSCIENCES
14:45-14:55	ATOM BIOSCIENCE
14:55-15:05	VIRIOM
15:05-15:15	INIVATA
15:15-15:25	GLADIATOR BIOSCIENCES
15:25-15:35	PHASEBIO
15:35-15:45	ADOCIA
15:45-15:55	ZYNERBA PHARMACEUTICALS
15:55-16:05	TERUISI PHARM

TARGOVAX

- COMPANY WEBSITE: www. targovax. com
- PRIMARY THERAPEUTIC AREA(S): Immunotherapy
- PHASE OF DEVELOPMENT: Ph I/II
- EXECUTIVE SUMMARY OF THE COMPANY:

Targovax' s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells.It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS - mutations known to drive cancer. The TG vaccine program has shown a signal of efficacy in a 32- patient trial with TG01 in resected pancreatic cancer.

ETHERNA IMMUNOTHERAPIES NV

- COMPANY WEBSITE: www.etherna.be
- PRIMARY THERAPEUTIC AREA(S): Immunotherapy
- PHASE OF DEVELOPMENT: Clinical Development – phase I/II
- EXECUTIVE SUMMARY OF THE COMPANY:

eTheRNA is a clinical stage developer of mRNA-based immunotherapies for cancer, focusing on therapies that activate the immune system by programming dentritic cells (DC) with synthetic mRNA. To date it has completed 4 clinical studies (Phase I and II) and has 3 studies underway. The company recently opened a new GMP facility which also provides contract manufacturing services. eTheRNA concluded a Series A financing in 2016 and is supported by a strong sector-specialised investor syndicate.
eTheRNA immunotherapies is a clinical stage developer of mRNA-based immunotherapies for cancer, focusing on therapies that prepare and activate the immune system by programming dentritic cells (DC) with synthetic mRNA. It also has an interest in infectious disease therapies.

ASTROCYTE PHARMACEUTICALS, INC.

- COMPANY WEBSITE: www.astrocytepharma.com
- PRIMARY THERAPEUTIC AREA(S): Nseurology
- PHASE OF DEVELOPMENT: Preclinical
- EXECUTIVE SUMMARY OF THE COMPANY:

Astrocyte is a small asset-centric CNS drug development company based in Cambridge, MA, USA. The company has raised $4.7M in private financing and been awarded $4M in NIH grants.
The primary therapeutic area is acute neurology which includs acute ischemic stroke (AIS), traumatic brain injury (TBI) and concussion, which are leading causes of death and disability worldwide.AST-004 is a novel small molecule A3R agonist that activates mitochondrial energy production in astrocytes and promotes multiple intrinsic neuroprotective mechanisms.

PRESENTING COMPANIES

CHINA FOCUS

MADISON VACCINES INCORPORATED (MVI)

- COMPANY WEBSITE: www.MadisonVaccines.com
- PRIMARY THERAPEUTIC AREA(S): Prostate Cancer
- PHASE OF DEVELOPMENT: Phase I/II
- EXECUTIVE SUMMARY OF THE COMPANY:

MVI products are plasmid DNA molecules encoding specific antigens. MVI-816 encodes prostatic acid phosphatase (PAP), a prostate-specific protein. MVI-118 encodes the ligand binding domain of the human androgen receptor, the key molecular driver of prostate cancer. Both candidates are simple to manufacture and have excellent stability. MVI agents are administered as a 100-microgram intradermal dose using a tuberculin syringe. Both MVI plasmid agents have demonstrated excellent pre-clinical and human clinical safety. MVI agents induce antigen-specific CD4+ and CD8+ T-cell responses to their targets when dosed intradermally and increase tumor-infiltrating lymphocytes (TILs) in prostate tumors. MVI plasmid DNA molecules are amenable to microneedle patch delivery systems that would further improve patient convenience.

HPBIO

- COMPANY WEBSITE: www.hpbio.co.kr
- PRIMARY THERAPEUTIC AREA(S):
  Obesity, Wound/Scar treat, Allergy, Neurodegenerative disease
- PHASE OF DEVELOPMENT: Preclinical
- EXECUTIVE SUMMARY OF THE COMPANY:

1.Obesity program: PPARgamma binding RNA aptamers; Adipocyte differentiation was over 80% inhibited and showed very reduced lipid accumulation
2.Allergy program: Histamine binding DNA aptamers and HDC (Histidine decarboxylase) binding DNA aptamers;Antihistamines DNA aptamers bind to specifically to Histamine and shows 85% reduction values in clinical samples.13. Wound/Scar free healing: Growth factors (Insulin, EGF, PDGF) receptor binding DNA aptamer; Growth factor agonist DNA aptamers has demonstrated exemplary results such as growth factor induced cell signaling activation.
4. Neurodegenerative disease:Establishment of In vitro BBB (Brain blood barrier)-SELEX set-up and Aptamer-exosome complexes; Development of Alzheimer' s disease target (Aβ, Tau) and Parkinson' s disease target (α-synuclein) binding aptamer for inhibiting protein plaques; Aptamer- Exosome complexes can cross the permeable in vitro BBB.

ELASMOGEN LTD

- COMPANY WEBSITE: www.elasmogen.com
- PRIMARY THERAPEUTIC AREA(S):
  Ophthalmology, oncology, inflammation, auto-immune diseases
- PHASE OF DEVELOPMENT: Late pre-clinical
- EXECUTIVE SUMMARY OF THE COMPANY:

Elasmogen's single-domain soloMERs are high affinity binding domains; they are small (9% of an antibody), stable proteins, have a fourth binding loop into their single domain format and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to bind cryptic or hidden epitopes such as enzyme or receptor binding sites. Our in-house programmes are focused on auto-inflammatory disease and oncology utilizing formats suitable for both site-specific and systemic delivery. Their remarkable stability enables non-receptor mediated intracellular localisation facilitating the targeting of novel therapeutic molecules and the potential to penetrate solid tumours. We are currently seeking new pharma partners.

ALPS GLOBAL HOLDING BERHAD

- COMPANY WEBSITE: www.alps-holdings.com
- PRIMARY THERAPEUTIC AREA(S): Oncology, Neurology, Common Diseases
- PHASE OF DEVELOPMENT:
  Merger & Acquisition phase; Look for strategic partner
- EXECUTIVE SUMMARY OF THE COMPANY:

The Biomarker can detect our hidden disease from 3 years up to 30 years in future. The Biomarker results are up to 90% accuracy and above. Currently our Biomarker Lab can detect up to 14 types of diseases via using different biomarker. Immunotherapy establish by ALPS is the effective ways for preventing, managing or preventing different cancers and diseases at early stage, for example: Natural Killer (NK) cell, Dendritic cell (DC), Cytokine-Induced Killer (CIK) cell and Chimeric Antigen Receptor (CAR) T cell. Currently, with the discovery of induced pluripotent stem (IPS) cells, ALPS can convert differentiated somatic cells into multipotent stem cells that have the capacity to generate all cell types of adult tissues. Because they're made from a person's own cells, they can potentially be manipulated to fix the disease-causing defect and then used to create healthy cells for transplant that won't be rejected by the immune system. In means, ALPS can help to regenerate the damage organ cells via culture the IPS cells.

HEXAELL BIOTECH

- COMPANY WEBSITE: www.hexaell.com
- PRIMARY THERAPEUTIC AREA(S): liver disease (liver failure)
- PHASE OF DEVELOPMENT: Pre-clinic
- EXECUTIVE SUMMARY OF THE COMPANY:

China has a large population that is affected by liver diseases. There are about 1 million new cases of liver failure each year. The 28-day mortality is as high as 50% in patients with acute liver failure. HepaCure bioartificial liver is an in vitro liver function support system, which can substitute hepatic function in a short period to prevent the manifestations of liver failure, promote the recovery of native liver function in patients with liver failure to avoid liver transplantation, or bridge patients to liver transplantation. By using such technology, Hexaell Biotech has finished pilot studies with more than 10 liver failure patients in China. Results showed reliable safety and outstanding clinical efficacy with >90% long-term survival rate.

MGI/BGI

- COMPANY WEBSITE: www.mgitech.cn
- PRIMARY THERAPEUTIC AREA(S):
  Cancer, prenatal, all health related diagnostics
- PHASE OF DEVELOPMENT: Products on market
- EXECUTIVE SUMMARY OF THE COMPANY:

The recent launch of sequencing platform MGISEQ-T7:
i) DNBseq technology comprising unique PCR-free error-free DNA nanoball arrays based on linear DNA amplification and cPAS sequencing chemistry with negligible signal loss in hundreds of sequencing cycles, and ii) advanced biochemical, fluidics, and optical systems resulting in the best performance to date: the highest throughput and shortest turn-around time. DNBseq technology delivers high quality 35-200 base single or pair-end reads with low duplicate rate, higher coverage in GC rich regions, and increased accuracy in detection of diagnostic mutations, especially indels. In addition, DNBseq has no molecular índex swapping providing index mis-assignments as low as 1 part per million even with single indexing. MGISEQ-T7 utilizes a revolutionary quadruple flow cell staging, which enables multiple flow cells with different read lengths and applications to be independently processed in a single run. This unique design allows users to combine multiple applications based on specific demands.

PRESENTING COMPANIES

CHINA FOCUS

HISTOGEN

Redefining Regenerative Medicine

- COMPANY WEBSITE: www.histogen.com
- PRIMARY THERAPEUTIC AREA(S): Aesthetic products and Orthopedic indications
- PHASE OF DEVELOPMENT:
  HSC660: Clinical Phase II; Skin Care: Market;Other Applications: Preclinical
- EXECUTIVE SUMMARY OF THE COMPANY:

Histogen is a regenerative medicine company developing patented technologies that stimulate the body' s stem cells to regenerate tissues andrestore youthful function.
Histogen' s lead product application is HSC660, a soluble formulation in clinical development as an injectable for hair regrowth.

PROMIS NEUROSCIENCES

- COMPANY WEBSITE: www.promisneurosciences.com
- PRIMARY THERAPEUTIC AREA(S): Central nervous system diseases (CNS)
- PHASE OF DEVELOPMENT:
  Preclinical development for Alzheimer' s, Parkinson' s and ALS
- EXECUTIVE SUMMARY OF THE COMPANY:

ProMIS is a development stage biotechnology company developing antibody therapeutics selectively targeting toxic oligomers, the root cause of neurodegenerative diseases; Alzheimer' s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson' s disease (PD).
PMN310: lead antibody therapeutic for Alzheimer' s disease selectively neutralizes the toxic oligomers of amyloid beta, widely considered a root cause of the disease. Preclinical studies demonstrate it blocks both the neurotoxicity and propagation of the toxic oligomers, without interfering with normal, non-toxic forms of amyloid beta.

VIRIOM

HOPE HEALTH HAPPINESS

- COMPANY WEBSITE: www.viriom.com
- PRIMARY THERAPEUTIC AREA(S): Viral infection (HIV and Hepatitis B virus)
- PHASE OF DEVELOPMENT:
  Elpida®: authorized to market; NRTI VM2500: preclinical/IND
- EXECUTIVE SUMMARY OF THE COMPANY:

A commercial and late-stage biotech company developing novel therapies and prophylactic medicines against HIV-1 and Hepatitis B Virus (HBV).
Elpida® (elsulfavirine), the best-in-class NNRTI that obtained first market authorization in 2017; novel fixed doze combination single pill regimens; low frequency (weekly) oral formulations; and long-acting injectable therapy and prophylaxis.
Viriom is also developing NRTI VM2500 - a highly potent prodrug of the antiviral tenofovir to treat HIV-1 and Hepatitis B patients. Viriom combines its extended release and long-acting injectable compounds with partnered therapies projecting curative potential.

ATOM BIOSCIENCE

ATOM BIOSCIENCE
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.

- COMPANY WEBSITE: www.atombp.com/en/
- PRIMARY THERAPEUTIC AREA(S):
  Kidneys disease, gout, hyperuricemia; Gastric cancer, colon cancer and breast cancer;
- PHASE OF DEVELOPMENT: Pre-clinical to Phase I
- EXECUTIVE SUMMARY OF THE COMPANY:

The current medications do not meet the requirement of treatment of gout due to the severe side effects of these drugs. ABP-671 showed a great inhibition of hURAT1 whose function is to increase the excretion of uric acid by the kidneys. ABP-671 demonstrated great efficacy in the animal models, excellent safety profiles, good enzymatic stability, good PK and several other good characteristics in its pre-clinical studies. ABP-671 is currently under Phase 1 clinical trials in the US. It shows superior lowering serum uric acid in recent first human study, which is much better than current gout drugs including URAT1 inhibitors such as Benzbromarone and Zurampic, and Xanthine oxidase inhibitors like Allopurinol and Uloric (Febuxostat). ABP-671 has showed a good human PK. The NOAEL of ABP-671 both in monkeys and rats is 500 mg/kg.

INIVATA

Inivata™

- COMPANY WEBSITE: www.inivata.com
- PRIMARY THERAPEUTIC AREA(S):
  Molecular diagnostics for lung cancer and other cancers
- PHASE OF DEVELOPMENT: Commercially available
- EXECUTIVE SUMMARY OF THE COMPANY:

InVisionFirstTM - Lung is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer (NSCLC). The test is intended to aid clinicians in treatment decisions for NSCLC patients.
InVisionSeqTM is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients.

GLADIATOR BIOSCIENCES

GLAdiator™ Biosciences

- COMPANY WEBSITE: In development
- PRIMARY THERAPEUTIC AREA(S): Oncology
- PHASE OF DEVELOPMENT: Pre-clinical
- EXECUTIVE SUMMARY OF THE COMPANY:

Current cancer treatments lack effective targeting and suffer from limited efficacy and unwanted off target effects. Using a platform discovered by Bayer HealthCare in collaboration with Stanford University, GLAdiator Biosciences seeks to address this need by selectively internalizing therapeutic payloads into targeted cancer cells. As former VP of Biologics Research at Bayer and Head of their US Innovation Center and now CEO of GLAdiator Biosciences, I would welcome the opportunity to elaborate on our company and discuss mutually beneficial opportunities to realize the value of this platform in the clinical setting.

PRESENTING COMPANIES

CHINA FOCUS

PHASEBIO

- COMPANY WEBSITE: Phasebio.com
- PRIMARY THERAPEUTIC AREA(S): Rare disease, Cardiopulmonary, PAH
- PHASE OF DEVELOPMENT: Phase II
- EXECUTIVE SUMMARY OF THE COMPANY:

PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots, which could restrict blood flow. Due to ticagrelor' s antiplatelet activity, patients on ticagrelor have an elevated risk of spontaneous bleeding. In addition, patients on ticagrelor who need urgent surgery cannot wait the recommended five days for ticagrelor' s effect to dissipate and are at increased risk of major bleeding during and after surgery. There are currently no known reversal agents approved or in clinical development for ticagrelor or any of the other antiplatelet drugs.

ADOCIA

- COMPANY WEBSITE: www.ADOCIA.com
- PRIMARY THERAPEUTIC AREA(S): Diabetes and Metabolism
- PHASE OF DEVELOPMENT: Up to, and including, Phase III.
- EXECUTIVE SUMMARY OF THE COMPANY:

ADOCIA employs its proprietary excipient library, BioChaperone®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism
Pipeline includes: Ultra-rapid insulin lispro | Modern premix of insulins glargine and lispro | Combination of pramlintide and insulin | Ready to use glucagon | Ready to use GLP2

ZYNERBA PHARMACEUTICALS

- COMPANY WEBSITE: zynerba.com
- PRIMARY THERAPEUTIC AREA(S):
  Rare and near-rare neuropsychiatric disorders
- PHASE OF DEVELOPMENT: Phase II
- EXECUTIVE SUMMARY OF THE COMPANY:

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and refractory epilepsies.Our lead asset, ZYN002, is a pharmaceutically manufactured cannabidiol (CBD), formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
ZYN002 is currently enrolling in a pivotal pediatric/adolescent study in Fragile X syndrome (granted orphan drug designation by the FDA). We are also enrolling a Ph2 pediatric/adolescent study in a group of rare refractory epilepsies, Developmental and Epileptic Encephalopathies (DEE). Data from both are expected in 2019.

ZHEJIANG TERUISI PHARMACEUTICAL

- COMPANY WEBSITE: www.teruisipharm.com
- PRIMARY THERAPEUTIC AREA(S): Oncology
- PHASE OF DEVELOPMENT: Phase I& Phase III
- EXECUTIVE SUMMARY OF THE COMPANY:

Zhejiang Teruisi Pharmaceutical Inc. is a biopharmaceutical company focuses on but not limited to mAb product development and manufacture. core technical teams came from reputable international pharmaceutical companies (J&J, BMS and GSK); they are the top-notch CMC experts with 25-28 year mAb product development and manufacture experiences. The company is on the promise of delivering quality Biopharmaceuticals through pre-clinical, clinical development and commercial manufacturing for worldwide market including US besides China.
Company had established the China' s first world class large scale commercial manufacture facility (4X5000 L = 20,000L) that met US/FDA, EU/EMA, ICH & cFDA multiple cGMP standards. The facility had been successfully validated and produced the phase 3 material for US/FDA phase 3 clinical trial. The company can provide one stop, full service CMC development and commercial manufacturing for international companies.
Company is looking for international partners for market collaborations (biosimilars and NMEs) as well as mAb CMO clients.

PRIVATE PITCH
CHINA FOCUS

FEATURED GUESTS

JIANGSU HENGRUI MEDICINE

A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017, established in 1970. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan and Germany. Hengrui currently has 4 China NMPA approved new molecular entities, as well as over 35 new molecular entities in clinical development in China, the United States, and Australia, across oncology, anesthesiology and pain management, immunology & inflammation, and cardiovascular and metabolic diseases.

Representatives

- Lianshan Zhang, President of Global R&D
- Paul Lu, US Head of Global Business Development
- Dong Chen, Director and China Head of Business Development
- Zhenyan Yan, Director of Global Business Development

PRIVATE PITCH
CHINA FOCUS

FEATURED GUESTS

CSPC PHARMACEUTICAL GROUP LTD

CSPC was recognized as the top brand for its compliance culture, ethical business and innovation.

Representatives

- Charles Wang, International CEO/President
- Ronald Walls, Head of Business Development

ORBIMED FOSUN PHARMA

A leading investment firm dedicated exclusively to the healthcare sector, with over US $13 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team of more than 100 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Mumbai, Shanghai, Herzliya and Hong Kong.

Representatives

- Nissi Darvish, Global BD Head of OrbiMed Israel
- Roy Amariglio, Vice President of OrbiMed Israel

FOSUN PHARMA

As a Shanghai and Hong Kong Stock Exchange Dual (A+H) listed company, Fosun is China's No.1 pharmaceutical & healthcare distributor, the No. 6 of domestic sales revenue of prescription drugs for hospitals, with sales revenue of more than 100 million RMB, and with 75 IND approvals since 2015, including 5 IND approvals by US FDA.

Representatives

- Anjiang Liu, Senior Advisor
- Ning Yuan, General Manager BD Department

SEQUOIA CAPITAL CHINA

Sequoia Capital China invests between $100,000 and $1 million in seed companies, between $1 million and $10 million in early venture, and between $10 million and $50 million in growth investments. Sequoia Capital China was founded in September 2005 and is based in Beijing, China with additional offices in Admiralty, Hong Kong and Shanghai, China. Sequoia Capital China operates as a subsidiary of Sequoia Capital. It invests in the healthcare sector across medical-treatment services, mobile healthcare, innovative medicine,

FEATURED GUESTS

generic and new medicine, diagnostic services, genetics services, lab services, medical treatment equipment and facilities, patient services, doctor-patient platforms,vertical medical consultation start-ups, product development services

Representative

- Lynn Yang, Managing Director

ZAI LAB

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since the founding in 2014, Zai lab has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates, and become a trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. It has built manufacturing capabilities to support the clinical and commercial production of our drug candidates in China, and expect to have further clinical production capabilities in the near future.

Representative

- Jonathan Wang, SVP & Head of Business Development

NORTHERN LIGHT VENTURE CAPITAL

A leading venture capital firm targeting early stage opportunities of innovation in Healthcare, TMT and Advanced Technology. It is established in 2005 and today it has $4.5 billion dollar managed capital. Leveraging successful investing and entrepreneurial expertise in both China and the United States, the NLVC team looks for partnering with world class entrepreneurs to build world class companies.

Representative

- Cynthia Cai, Senior Advisor

QILU PHARMACEUTICAL

One of the leading pharmaceutical companies in China, focusing on the development, manufacturing and marketing of innovative and generic drugs in various therapeutic areas such as Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu is committed to build world class R&D teams around the globe and has established innovative drug discovery centers in Boston, Seattle, San Francisco, and Shanghai. Qilu has built state of art manufacturing facilities, which have been approved by USFDA, EMA, MHRA, PMDA of Japan, and other regulatory authorities. Qilu has assembled top sales and marketing teams which ranked number one in China for the past ten years. Qilu aims to establish extensive cooperation with domestic and international partners to bring innovative drugs to the China market and help the wellbeing of Chinese patients.

Representative

- Qun Dang, Vice President

PRIVATE PITCH
CHINA FOCUS

FEATURED GUESTS

COWIN CAPITAL GROUP

同创伟业 COWIN CAPITAL

Cowin was established in 26/6/2000 year as China's first professional private placement Equity investment company. Cowin Capital has 18 years of experience of capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 more successfully exit. Our company focus on investing on pioneering enterprise in long-term basis, always keeping steady development. Our company is being in the lead in China, which operates as an excellent domestic investment organization with extraordinary return. Cowin Capital was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ.

Representative

- Yan Zhang, Investment Director

FCHIA TAI TIANQING PHARMACEUTICAL GROUP

正大天晴 CHIA TAI TIANQING

Founded in 1969, headquartered in Lianyungang and Nanjing, Jiangsu province, Chia Tai Tianqing (CTTQ) is a leading pharmaceutical company with integrated R & D, manufacturing, distribution, marketing, and sales in China. Its holding company Sino Biopharmaceutical Limited has been listed in Hong Kong stock market (HK 1177) since 2003. CTTQ is the market leader in drugs treating liver diseases in China since mid-1990s. With marketed drugs for the treatment of liver disease, cancer, cardiovascular, respiratory and infectious disease, etc., CTTQ generated sales revenue of 2.7 billion USD in 2017.

Representatives

- Weigang Wang, Senior Director
- Hanjian Wang, BD Director

SHENZHEN SALUBRIS PHARMACEUTICALS

信立泰药业 SALUBRIS

Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution, and service of professional pharmaceutical and healthcare products to bring healthier and happier life to people worldwide through world-leading quality and innovations. In 2017, Salubris achieved >$750M USD in sales and ~$230M USD in profit (based on 2017 exchange ratios). Salubris is focused on cardiovascular and metabolic diseases, and oncology, and has completed several partnerships with US/EU companies in 2017/2018. Salubris focuses on the newest generation of innovative and specialty medicines, and has been recognized as an advanced technology enterprise and innovative high-tech company.

Representatives

- Sam Murphy, VP and Head of International Business Development
- John Li, CEO of Salubris Biotherapeutics

FEATURED GUESTS

SIMCERE PHARMACEUTICAL GROUP

Simcere was founded in 1995 with a corporate mission of "Making Better Medicine Available to Patients Sooner". During the past 23 years, Simcere has established two R&D centers, two sales subsidiaries and four GMP facilities with over 4500 employees on board. Simcere is dedicated in the development and manufacturing of innovative medicines and branded generics in the therapeutic areas of oncology, neurology, rheumatology, immunology, anti-infectives, and cardiovascular diseases. The company is also actively exploring external opportunities with global partners to further advance internal capabilities. Currently Simcere has built long-term alliance with Amgen, BMS, Daiichi Sankyo and many others. The company has collectively invested over $300 million into oversea biotech companies and 8 global venture capital funds including MPM, ABG, PIF, GT & etc.

Representative

- Lilly Zhang, Senior Director of Business Development

BUCHANG PHARMA

Established in 1993 and listed in Shanghai Stock Exchange in 2016 (SH 603858), with 15 pharmaceutical factories, more than 180 pipelines in different stages, and more than 2,000 sale rep. offices. Buchang specializes in the R&D, production and sale of TCM patent medicines, supplemented by many fields, i.e., hi-tech industry and health industry. The Company has set up its production bases in Shandong, Shaanxi, Hebei and the Northeast China, with its marketing network spreading all over major provinces of China.

Representative

- Zhankai Qi, Global BD Head

3SBIO

3SBio is a fully-integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focused on building an innovative product pipeline, with over 30 products candidates under development. 3SBio's manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically- synthesized molecules, with production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Cuomo, Italy. 3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for additional information.

Representative

- Tom Folinsbee, Director of Corporate Development

PRIVATE PITCH
CHINA FOCUS

AGENDA

Time	Session	Exclusive Audiences
9:00-11:30	Biotech Company Pitch I	Investors and Chinese Pharma
13:30-14:30	Biotech Company Pitch II	Investors and Chinese Pharma
15:00-16:00	Chinese Company Showcase	Investors and Global Pharma
16:00-17:00	Medical Device Showcase	Investors

PRESENTING COMPANIES (5 MINUTES EACH)

Biotech Company Pitch I

- ASTROCYTE PHARMACEUTICALS
- BERLIN CURES
- ACTOBIO THERAPEUTICS
- PNEUMAGEN LIMITED
- SUMMIT THERAPEUTICS
- GLADIATOR BIOSCIENCES
- AUTOLUS THERAPEUTICS
- LIPAC ONCOLOGY
- ENCENDIA THERAPEUTICS
- AUM BIOSCIENCES
- ARIZ PRECISION MEDICINE

Biotech Company Pitch II

- ETHERNA
- ELASMOGEN
- MOLECULAR TARGETING TECH-
- NOLOGIES
- HPBIOLAB INC
- ONCONOVA THERAPEUTICS
- TARGOVAX

SPONSORS

GOLD SPONSOR

CSPC 石药集团 | McDermott Will & Emery

SILVER SPONSOR

华森制药 PHARSCIN PHARMA

PARTNERS

EBD GROUP
SOLEBURY TROUT
E药经理人
贝壳社 BioClub
AZBIO
svb Silicon Valley Bank
前途汇 QIANTUHUI
STAR TREE VENTURES
LIFE SCIENCE NATION Connecting Products, Services & Capital
PhIRDA 中国药促会

Premium Partnering Service: All-in-One

Identify Targets

- Evaluate the company portfolio and strategic plan
- Identify potential targets

01

Promotion

- Increase visibility in China capital market with
  a powerfulnetwork of relationships in China
  a professional marketing team
  a public platform with 5000+ subcsribers
- Roadshow presentation on MyBioGate online platform

02

Outreach

- Assist in the preparation of a clear, concise, and compelling pitch deck
- Arrange conference calls with targets

03

Partnering Meetings

- Invite targets to China Focus conference
- Facilitate one-on-one meetings
- Assist in the pitch to 200+ executives and investors

04

Out-Licensing| In-Licensing | Fundraising | R&D Partnership| M&A

An Ecosystem to Build Successful Partnership

China Focus International Conferences

Research Team of 100+ PhDs/Consultants

Powerful Network

Online Roadshow Platform

MyBioGate News With 5000+ Subscribers

CUBIO Innovation Center

Youwen Dai (China)
Youwen.Dai@mybiogate.com
+86 151-5185-2853

Ginger Ding(US)
Ginger.Ding@mybiogate.com
+1 405-708-1897

We are CUBIO

CUBIO INNOVATION CENTER

A biomedical incubator provides healthcare startups with access to a wide platform of lab infrastructure to refine their solutions and connections of U.S. innovation with overseas market resources and networks. Our mission is to provide an unparalleled platform to serve innovators unmet needs in the biotechnology field of the Texas and the world.

What we do ?

Investment: Angel, pre-seed and seed funding for:

Therapeutics
Medical Devices
Diagnostics
IT Health & Analytics Nanomedicine

Office space:

Furnished office space including conference-rooms, wireless internet, electricity, printing services, and more...
Co-working space as your local office
Common space with kitchen facilities.
A reception area.

CRO service:

Core facility for biomedical ventures
Regulatory affairs services

Incubation:

Innovation ecosystem development
Startup incubation
Consulting services
Mentoring & training

7707 Fannin Street, Ste. 200, Houston, TX 77054
1-832-491-0069
https//cubiohouston.com

JAN 6, 2019
SAN FRANCISCO CA

QR code to follow us on WeChat

ORGANIZER: MYBIO
CO-ORGANIZER: iMeta 艾美达 CUBIO INNOVATION CENTER

Web: events.mybiogate.com;
Email: info@mybiogate.com